Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2025 12:12 ET | Source: Spherix Global Insights

Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights

Exton, Pennsylvania, Aug. 28, 2025 (GLOBE NEWSWIRE) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S....
August 28, 2025 10:13 ET | Source: Spherix Global Insights

Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights

EXTON, PA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH)...
August 26, 2025 09:58 ET | Source: Spherix Global Insights

Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds

EXTON, PA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to switch their advanced...
August 25, 2025 10:14 ET | Source: Spherix Global Insights

US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights

EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in...
August 21, 2025 09:12 ET | Source: Spherix Global Insights

Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights

EXTON, PA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection...
August 19, 2025 10:59 ET | Source: Spherix Global Insights

Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...
August 14, 2025 13:30 ET | Source: Spherix Global Insights

Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care

EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging...
August 07, 2025 09:34 ET | Source: Spherix Global Insights

Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights

EXTON, PA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies...
August 06, 2025 11:29 ET | Source: Spherix Global Insights

Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors...
August 06, 2025 10:16 ET | Source: Spherix Global Insights

Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is...